<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841201</url>
  </required_header>
  <id_info>
    <org_study_id>IMMUNIB</org_study_id>
    <nct_id>NCT03841201</nct_id>
  </id_info>
  <brief_title>Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma</brief_title>
  <official_title>IMMUNIB - An Open-label, Single-arm Phase II Study of Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisai GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, open-label, single arm, multicenter phase II trial for the evaluation&#xD;
      of efficacy and feasibility (as determined by safety and tolerability) of immunotherapy with&#xD;
      nivolumab in combination with lenvatinib for patients with multinodular, advanced stage&#xD;
      hepatocellular carcinoma in first line therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single-arm, multicenter phase II trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) according to RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>Number and percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability (AEs, SAEs according to NCI-CTCAE V 4.03)</measure>
    <time_frame>6 months</time_frame>
    <description>Type, incidence and severity of AEs, SAEs according to NCI-CTCAE V 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) according to iRECIST</measure>
    <time_frame>6 months</time_frame>
    <description>Number and percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) according to iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-progression (TTP)</measure>
    <time_frame>6 months</time_frame>
    <description>Time from the date of treatment allocation to the date of first observed disease progression (investigator assessment according to RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>Time from the date of treatment allocation to the date of first observed disease progression (investigator assessment according to RECIST 1.1) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>Time from the date of treatment allocation to the date of death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational research</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation of biomarkers potentially associated with clinical efficacy (OS, PFS and ORR) from lenvatinib plus nivolumab by molecular quantitation of mRNA expression of parameters like e.g. PD-1, PD-L1 and PD-L2, immune cell infiltrates (IGHM, CD3, CD8, FOXP3, CD68, CD205), chemokines (CXCL9, CXCL10, CXCL13) and invasion markers (MMP7, MMP9).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenvatinib peroral qd (8 mg for patients with body weight &lt;60kg and 12 mg for patients with body weight ≥ 60kg)&#xD;
Nivolumab i.v. q2w (240mg fixed dose IV) max. 36 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Study treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>iv infusion</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Study treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fully-informed written consent.&#xD;
&#xD;
          2. Males and females ≥ 18 years of age&#xD;
&#xD;
             *There are no data that indicate special gender distribution. Therefore patients will&#xD;
             be enrolled in the study gender-independently.&#xD;
&#xD;
          3. Unresectable, multinodular tumour, not eligible for resection or local ablation&#xD;
&#xD;
          4. Histologically confirmed diagnosis of hepatocellular carcinoma&#xD;
&#xD;
          5. Has a Child-Pugh Classification score ≤ 6 for assessed liver function within 7 days&#xD;
             before allocation (Appendix 4: Child-Pugh Score)&#xD;
&#xD;
          6. At least one measurable site of disease as defined by RECIST 1.1 criteria with spiral&#xD;
             CT scan or MRI.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.&#xD;
&#xD;
          8. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          9. Adequate bone marrow, hepatic and renal function including the following:&#xD;
&#xD;
               -  Haemoglobin ≥ 10.0 g/dL, absolute neutrophil count ≥ 1,500 /µL, platelets ≥70,000&#xD;
                  /µL;&#xD;
&#xD;
               -  Total bilirubin ≤ 3.0 mg/dL upper normal limit;&#xD;
&#xD;
               -  AST (SGOT), ALT (SGPT) ≤ 5 x upper normal limit;&#xD;
&#xD;
               -  International normalized ratio (INR) ≤1.25;&#xD;
&#xD;
               -  Albumin ≥ 30 g/dL;&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x upper normal limit OR measured or calculated creatinine&#xD;
                  clearance (according to Cockcroft-Gault) ≥30 mL/min for participant with&#xD;
                  creatinine levels &gt;1.5 × institutional ULN (GFR can also be used in place of&#xD;
                  creatinine or CrCl)&#xD;
&#xD;
         10. Female patients with reproductive potential must have a negative urine or serum&#xD;
             pregnancy test within 7 days prior to start of trial. Women must not be breastfeeding.&#xD;
&#xD;
         11. If patient has concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV)&#xD;
             infection, meets the following criteria:&#xD;
&#xD;
               -  Patients with HBV or HCV infection should be monitored for viral levels during&#xD;
                  study participation.&#xD;
&#xD;
               -  Patients with detectable hepatitis B surface antigen (HBsAg) or detectable HBV&#xD;
                  DNA should have HBV DNA &lt; 100 IU/ml and should be managed per local treatment&#xD;
                  guidelines.&#xD;
&#xD;
             Controlled (treated) hepatitis B subjects will be allowed if they started treatment at&#xD;
             the time point of enrollment into the study by the latest and treatment is continued&#xD;
             during study participation and for ≥ 6 months after end of study treatment.&#xD;
&#xD;
             - HCV patients with with advanced HCC are mostly not treated for their HCV infection.&#xD;
             However, patients treated for HCV are considered suitable for inclusion if antiviral&#xD;
             therapy has been completed ≥ 30 days prior to first administration of study drug.&#xD;
&#xD;
         12. The patient is willing and able to comply with the protocol for the duration of the&#xD;
             study, including hospital visits for treatment and scheduled follow-up visits and&#xD;
             examinations.&#xD;
&#xD;
         13. WOCBP must agree to follow instructions for method(s) of contraception for a period of&#xD;
             30 days (duration of ovulatory cycle) plus the time required for the investigational&#xD;
             drug to undergo 5 half-lives. The terminal half-lives of nivolumab is approximately 25&#xD;
             days. WOCBP should use an adequate method to avoid pregnancy for approximately 5&#xD;
             months (30 days plus the time required for nivolumab to undergo 5 half-lives) after&#xD;
             the last dose of investigational drug.&#xD;
&#xD;
         14. Males who are sexually active with WOCBP must agree to follow instructions for&#xD;
             method(s) of contraception for a period of 90 days (duration of sperm turnover) plus&#xD;
             the time required for the investigational drug to undergo 5 half-lives. The terminal&#xD;
             half-lives of nivolumab is approximately 25 days. Males who are sexually active with&#xD;
             WOCBP must continue contraception for approximately 7 months (90 days plus the time&#xD;
             required for nivolumab to undergo 5 half-lives) after the last dose of investigational&#xD;
             drug. In addition, male subjects must be willing to refrain from sperm donation during&#xD;
             this time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous systemic therapy in the first-line setting.&#xD;
&#xD;
          2. Patients on a liver transplantation list or with advanced liver disease as defined&#xD;
             below:&#xD;
&#xD;
               -  Encephalopathy&#xD;
&#xD;
               -  Untreatable Ascites.&#xD;
&#xD;
          3. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.&#xD;
&#xD;
          4. Prior organ allograft or allogeneic bone marrow transplantation.&#xD;
&#xD;
          5. Local therapies ongoing or completed &lt;4 weeks prior to the baseline scan.&#xD;
&#xD;
          6. Thrombotic or embolic events such as cerebrovascular accident (including transient&#xD;
             ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months&#xD;
             prior to the first dose of study drug with the exception of thrombosis of a segmental&#xD;
             portal vein.&#xD;
&#xD;
          7. Prior, systemic anti-cancer chemotherapy, radiotherapy administered &lt;4 weeks prior to&#xD;
             study entry, endocrine- or immunotherapy or use of other investigational agents.&#xD;
&#xD;
          8. History of (non-infectious) pneumonitis that required steroids or current pneumonitis.&#xD;
&#xD;
          9. Major surgery within 4 weeks of starting the study. Patients must have recovered from&#xD;
             effects of major surgery.&#xD;
&#xD;
         10. Malignancies other than disease under study within 5 years prior to inclusion, with&#xD;
             the exception of those with a negligible risk of metastasis or death (e.g., expected&#xD;
             5-year OS &gt; 90%) treated with expected curative outcome (such as adequately treated&#xD;
             carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized&#xD;
             prostate cancer treated surgically with curative intent, ductal carcinoma in situ&#xD;
             treated surgically with curative intent)&#xD;
&#xD;
         11. Uncontrolled hypertension.&#xD;
&#xD;
         12. Clinically significant cardiovascular disease.&#xD;
&#xD;
         13. Any serious or uncontrolled medical disorder or active infection that, in the opinion&#xD;
             of the investigator, may increase the risk associated with study participation, study&#xD;
             drug administration, or would impair the ability of the subject to receive study drug.&#xD;
&#xD;
         14. Proteinuria (≥2g/24h)&#xD;
&#xD;
         15. Psychiatric disorders or altered mental status precluding understanding of the&#xD;
             informed consent process and/or compliance with the study protocol.&#xD;
&#xD;
         16. Subjects with a history of or current CNS metastases. A scan to confirm the absence of&#xD;
             brain metastases is not required. Patients with unknown CNS metastatic status and any&#xD;
             clinical signs indicative of CNS metastases are eligible if CNS metastases are&#xD;
             excluded using CT and/or MRI scans.&#xD;
&#xD;
         17. Pregnant or breast-feeding women.&#xD;
&#xD;
         18. Immunocompromised patients, e.g. patients who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV).&#xD;
&#xD;
         19. Subjects with active, known, or suspected autoimmune disease. Subjects with Type I&#xD;
             diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only&#xD;
             requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or&#xD;
             alopecia) not requiring systemic treatment are permitted to enroll. For any cases of&#xD;
             uncertainty, it is recommended that the medical monitor be consulted prior to signing&#xD;
             informed consent.&#xD;
&#xD;
         20. Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration. Inhaled or topical steroids, and adrenal&#xD;
             replacement doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of&#xD;
             active autoimmune disease.&#xD;
&#xD;
         21. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4&#xD;
             antibody, or any other antibody or drug specifically targeting T-cell co-stimulation&#xD;
             or checkpoint pathways.&#xD;
&#xD;
         22. All toxicities attributed to prior anti-cancer therapy other than hearing loss,&#xD;
             alopecia and fatigue must have resolved to Grade 1 (NCI CTCAE version 4.03) or&#xD;
             baseline before administration of study drug.&#xD;
&#xD;
         23. &gt; Grade 1 peripheral neuropathy according to CTCAE version 4.03&#xD;
&#xD;
         24. Patients who have received a live vaccine within 30 days prior to enrolment.&#xD;
&#xD;
         25. History of allergy or hypersensitivity to study drugs or any constituent of the&#xD;
             products&#xD;
&#xD;
         26. Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the first dose of&#xD;
             study treatment.&#xD;
&#xD;
         27. Patient who has been incarcerated or involuntarily institutionalized by court order or&#xD;
             by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.&#xD;
&#xD;
         28. Patients who are unable to consent because they do not understand the nature,&#xD;
             significance and implications of the clinical trial and therefore cannot form a&#xD;
             rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arndt Vogel, MD</last_name>
    <phone>+49 176 1 532</phone>
    <phone_ext>9590</phone_ext>
    <email>vogel.arndt@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel W Mueller, PhD</last_name>
    <phone>+49 69 7601</phone>
    <phone_ext>4125</phone_ext>
    <email>mueller.daniel@ikf-khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Vogel, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

